Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.36 -2.3%	$3.27	$2.71 ▼ $4.73	$643.53M	1.5	991,233 shs	635,966 shs
ACAD ACADIA Pharmaceuticals	$21.60 -3.1%	$16.87	$13.40 ▼ $25.23	$3.62B	0.47	1.94 million shs	1.45 million shs
HCM HUTCHMED	$13.77 -0.6%	$14.08	$11.51 ▼ $21.50	$2.40B	0.55	100,832 shs	87,577 shs
IMVT Immunovant	$14.87 -0.1%	$14.99	$12.72 ▼ $34.47	$2.53B	0.75	1.20 million shs	1.46 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-2.33%	+4.35%	-5.35%	-2.61%	0.00%
ACAD ACADIA Pharmaceuticals	-3.10%	-1.73%	+47.95%	+10.20%	+47.74%
HCM HUTCHMED	-0.65%	+2.76%	-7.27%	-16.34%	-26.21%
IMVT Immunovant	-0.13%	+2.84%	-7.93%	-27.82%	-49.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.3124 of 5 stars	3.5	0.0	3.8	2.5	0.6
ACAD ACADIA Pharmaceuticals	3.5013 of 5 stars	3.3	2.0	3.9	4.2	1.3
HCM HUTCHMED	2.0046 of 5 stars	3.0	2.0	2.2	0.0	1.9
IMVT Immunovant	2.2694 of 5 stars	4.5	0.0	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	63.69% Upside
ACAD ACADIA Pharmaceuticals	2.64	Moderate Buy	$26.83	24.23% Upside
HCM HUTCHMED	2.00	Hold	$19.00	37.98% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	157.79% Upside

Current Analyst Ratings Breakdown

Latest ABUS, IMVT, HCM, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$20.00 ➝ $23.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$26.00 ➝ $26.00
5/19/2025	ACAD ACADIA Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$24.00 ➝ $28.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $30.00
5/19/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $32.00
5/16/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/13/2025	HCM HUTCHMED	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
4/28/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.40M	100.50	N/A	N/A	$0.63 per share	5.33
ACAD ACADIA Pharmaceuticals	$996.28M	3.63	N/A	N/A	$2.63 per share	8.21
HCM HUTCHMED	$630.20M	3.81	$0.56 per share	24.51	$4.27 per share	3.22
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.41	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	7/30/2025 (Estimated)
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.69	28.42	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
HCM HUTCHMED	$100.78M	N/A	0.00	9.43	N/A	N/A	N/A	N/A	6/18/2025 (Estimated)
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)

Latest ABUS, IMVT, HCM, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
HCM HUTCHMED	0.07	2.81	2.68
IMVT Immunovant	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ACAD ACADIA Pharmaceuticals	96.71%
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ACAD ACADIA Pharmaceuticals	28.30%
HCM HUTCHMED	3.60%
IMVT Immunovant	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	181.91 million	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
HCM HUTCHMED	1,760	174.32 million	168.04 million	Not Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable

ABUS, IMVT, HCM, and ACAD Headlines

Recent News About These Companies

Immunovant (NASDAQ:IMVT) Shares Gap Up Following Strong Earnings

May 31 at 1:19 AM | americanbankingnews.com

Immunovant (NASDAQ:IMVT) Shares Gap Up on Earnings Beat

May 30 at 10:05 AM | marketbeat.com

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

May 30 at 10:00 AM | zacks.com

Immunovant (NASDAQ:IMVT) Posts Earnings Results, Beats Expectations By $0.08 EPS

May 30 at 9:49 AM | marketbeat.com

Immunovant, Inc. Reports Strategic Progress and Financial Results

May 30 at 12:17 AM | tipranks.com

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

May 29 at 4:10 PM | msn.com

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

May 29 at 7:00 AM | globenewswire.com

Immunovant (IMVT) to Release Earnings on Wednesday

May 29 at 1:27 AM | marketbeat.com

H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock

May 28 at 4:31 PM | msn.com

Immunovant (IMVT) Expected to Announce Earnings on Wednesday

May 28 at 1:29 AM | americanbankingnews.com

Nuveen Asset Management LLC Sells 189,759 Shares of Immunovant, Inc. (NASDAQ:IMVT)

May 26, 2025 | marketbeat.com

Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT)

May 26, 2025 | marketbeat.com

Woodline Partners LP Sells 772,251 Shares of Immunovant, Inc. (NASDAQ:IMVT)

May 24, 2025 | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Two Seas Capital LP

May 23, 2025 | marketbeat.com

Rafferty Asset Management LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)

May 22, 2025 | marketbeat.com

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

May 21, 2025 | businesswire.com

Vestal Point Capital LP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)

May 21, 2025 | marketbeat.com

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $38.33

May 21, 2025 | americanbankingnews.com

Tyro Capital Management LLC Has $3.75 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)

May 20, 2025 | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts

May 20, 2025 | marketbeat.com

Ensign Peak Advisors Inc Cuts Position in Immunovant, Inc. (NASDAQ:IMVT)

May 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, IMVT, HCM, and ACAD Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.36 -0.08 (-2.33%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.34 -0.02 (-0.60%)

As of 05/30/2025 05:43 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.60 -0.69 (-3.10%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$21.05 -0.55 (-2.54%)

As of 05/30/2025 06:13 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$13.77 -0.09 (-0.65%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$13.83 +0.06 (+0.44%)

As of 05/30/2025 06:13 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$14.87 -0.02 (-0.13%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$14.85 -0.02 (-0.13%)

As of 05/30/2025 07:13 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time